New Frontiers in Management and Treatment for Soft Tissue Sarcoma

Dear Colleagues,

Sarcomas are a rare and heterogeneous group of tumors that can arise in different types of body tissues, representing the 1% of neoplasms affecting both adults and children. They are usually caused by a variety of factors, such as exposure to chemical compounds, radiation, infections, and genetic diseases. Sarcomas can be divided into two large families: sarcomas of soft tissues (muscles, tendons, ligaments, cartilage, adipose tissue, blood vessels or lymphatics and nerves) and sarcomas of bone. Sarcomas are very heterogeneous tumors both biologically and for their clinical behavior. Indeed, the management of these diseases requires a multidisciplinary team consisting of a wide range of members, such as oncologists, endocrinologists, pathologists, nuclear medicine specialists, radiologists, and molecular biologists. Sarcoma mortality rate is relatively high: global survival after 5 years from the diagnosis is around 65%, even though, in recent years, an improvement of survival has occurred thanks to the improvement of screening strategies, diagnostic tools, and surgical techniques. Less defined is the role of chemotherapy and radiotherapy in modifying the prognosis both in adjuvant and metastatic disease.

In this Special Issue, we invite original studies and review articles on the diagnosis, biology, genetic and epigenetic aspects, epidemiology, and novel therapeutic options of sarcomas. The Special Issue also encourages papers evaluating aspects related to the quality of life of patients with sarcomas and any therapies and/or support procedures to improve patients’ quality of life.

Dr. Salvatore Tafuto
Dr. Antonio Pizzolorusso
Dr. Lucia Cannella
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• soft tissue sarcomas
• sarcoma management
• multidisciplinary approach
• chemotherapy
• target therapy
• immunotherapy
• sarcoma biomarkers
• epigenomics